BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kyntra Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Kyntra Bio's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05970172-873@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT05970172)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chr
 onic Kidney Disease\nEstimated primary completion: 30 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/roxadustat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05970172
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722988-873@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT07722988)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Myelodysplastic Syndromes.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592
 ) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
 \nEstimated primary completion: September 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/roxadustat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07722988
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
